ITM Isotope Technologies Munich SE (ITM), a leading radiopharmaceutical biotech company, today announced that it will unveil ...

ORR of 35% in previously treated squamous NSCLC patients with responses across PD-L1 TPS scores Differentiated structure of ...

Icotrokinra is a first-in-class investigational targeted oral peptide that selectively blocks the IL-23 receptor 1 Filing ...

During a live event, Kit Yu Lu, MD, discussed data on antibody-drug conjugates in HR+, HER2- breast cancer including the ...

In a phase 1b trial, tarlatamab plus an anti-PD-L1 in first-line maintenance achieves a median survival of more than 2 years ...

Agentic artificial intelligence startup Druid AI S.A. says it’s ready to scale up the adoption of its enterprise-grade ...

CrowdStrike bets on agentic AI with new Falcon data layer and security operations center agents - SiliconANGLE ...

Combination therapy of casdatifan and cabozantinib shows promising efficacy and manageable safety in patients with advanced ...

Instil Bio (TIL) announced that ImmuneOnco Biopharmaceuticals presented preliminary efficacy and safety data of ‘2510 as monotherapy in a Phase 1 ...

ENDO 2025 featured the latest research on novel therapies for adrenal and neuroendocrine conditions, new data on various ...

RFSD was accredited with its highest score from a state performance measurement since before the pandemic, but gaps between ...